Navigation Links
ResQ-Valve With CPR In Cardiac Arrest Patients To Be Assessed By National Study

It has been proposed by researchers at Medical College of Wisconsin to conduct a large-scale clinical trial to assess the improvement in survival rate in cardiac arrest patients, given CPR and ResQ-Valve//.

The study would be funded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. The ResQ-Valve Study offers a promise in the emergency management of cardiac arrest and severe traumatic injury, and would be studied under the shelter of the Resuscitation Outcomes Consortium (ROC).

The organization has planed to implement a large-scale trial to evaluate the survival and neurological outcome, in addition to the hospital discharge factor. Dr. Tom P. Aufderheide, professor of emergency medicine at the Medical College of Wisconsin has been elected to be the principal investigator for the study.

A sum of $1.5 million would be sanctioned for the Medical College to cover training costs and improve local infrastructure facilities. If the new treatment strategy were found to be safe and efficient, the silent prayers of numerous cardiac arrest patients would be answered soon.


'"/>




Page: 1

Related medicine news :

1. Cardiac diseases develop early
2. Heart problems detected better with a Cardiac MRI
3. Cardiac events better treated with intense cholesterol-lowering regime
4. Sudden Cardiac Death due to inherited Heart Disease
5. Vasopressin Found To Boost Survival In Sudden Cardiac arrest
6. Stem Cells From Bone Marrow Found To Improve Cardiac Functioning After A Heart Attack
7. Cardiac – Rehabilitation Programs Beneficial for Heart Patient
8. Cardiac Valve Disease Linked To Genes
9. Stanford Medical Center Implements The First Virtual Cardiac Ultrasound
10. Prevent Cardiac Problems And Laugh Your Way To Good Health
11. Higher Statin Dose Safely Reduces Stroke and Cardiac Arrest

Post Your Comments:
(Date:11/9/2009)...ire-USNewswire/ -- New Mayo Clinic research has fo...dramatically reduces patient hospital stay and rec...s week at the North Central Section of the America..., (Logo: http://www.newscom.com/cgi-bin/prnh/20...l audio and video resources, including excerpts fr...
(Date:11/9/2009)...wire/ -- At a time when the 250,000+ eligible Medi...d about finding affordable health insurance, they ..., The Today,s Options® Preferred Provider ...s a cost-effective and comprehensive alternative t... People with Medicare can choose to sign up for t...
(Date:11/9/2009)... our current campaign finance system ,, WASHIN... Congress who noted "no" on health care reform leg...llion more in campaign donations from health insur...e legislation to overhaul of the nation,s health c...alition of campaign reform groups. ,, "The heal...
(Date:11/9/2009)... , , WHAT: All PETCO stores nationwide will...facilitated by specially trained in-store nutritio...t 2 p.m. During the 30-minute, works...needs of, their dogs and cats, have a...ood pet nutrition, receive an assessment of their ...
(Date:11/9/2009)... and the University of Florida Proton Therapy Inst...n therapy for St. Jude patients. The announcement ...o evaluate the use of proton therapy for rare brai..., Under the clinical protocol, St. Jude will ref...oton Therapy Institute in Jacksonville, Fla. The p...
Breaking Medicine News(10 mins):Health News:Mayo Researchers Find Robotic Repair for Vaginal Prolapse Has Significant Benefits 2Health News:Mayo Researchers Find Robotic Repair for Vaginal Prolapse Has Significant Benefits 3Health News:Maine Residents With Medicare Searching for Affordable and Innovative Insurance Have Competitive Medicare Advantage Option 2Health News:'No' Votes on Health Care Bill Received $2.3 Million More from Health Insurance Industry 2Health News:St. Jude and UF Proton Therapy Institute to begin proton therapy clinical trial 2
...ustralians face increasingly large-scale,health ri...onment, ranging from,increases in weather extremes...health., Twelve of Australias top health and medic...ustralians., Released today by Research Australia,...
...research tracks the spread of HIV from Africa to A...s) -- New research into the genetic history of HIV...in Haiti during the middle of the last century, pr... into how HIV evolves and moves from place to plac...
...N, Pa., Oct. 30 ViroPharma Incorporated,(Nasdaq: ...he third quarter,and nine-months ended September 3... Clinical:, -- Patient enrollment began in a Pha...stem cell transplant patients; study enrollment ex...
...es Fiscal Year EPS Outlook for One-time Tax Benefi...e Company (NYSE: PG ) announced net sales growth ... Every reportable segment delivered,mid-single dig... Fabric & Home Care, Baby & Family Care and Groomi...
...CETON, N.J., Oct. 30 Medarex, Inc.,(Nasdaq: MEDX... at the,JPMorgan Small/Mid Cap Conference in Bosto...Time. Medarex,s presentation will be webcast live ...arex.com . About Medarex Medarex is a biopharmac...
...JOSEPH, Mich., Oct. 30 GeneGo, Inc., the leading,...t Elan Pharmaceuticals,Inc. licensed its flagship ...l be available to all scientists in research. Meta... very pleased that Elan chose GeneGo and we have h...
Other Medicine News:Health News:Healthy planet, places and people at risk 2Health News:AIDS Stopped in Haiti Before U.S. 2Health News:AIDS Stopped in Haiti Before U.S. 3Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 2Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 3Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 4Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 5Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 6Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 7Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 8Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 9Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 10Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 2Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 3Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 4Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 5Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 6Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 7Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 8Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 9Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 10Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 11Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 12Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 13Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 14Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 15Health News:P&G Reports EPS of $0.92, Up 16% Behind 8% Sales Growth 16
(Date:11/9/2009)...ROCKVILLE, Md., Nov. 9 OriGene Tec... Technology in Sweden has adopted its VERIFY Tagge...an Protein Atlas program. This program is funded b...set up to explore the human proteome systematicall...h quality mono-specific antibodies in a high throu...
(Date:11/9/2009)...ST. LOUIS, Nov. 9, 2009 ...E: PFE ) today announced that they have entered i...Chesterfield Village Research Center located in Ch... Monsanto will acquire the property from Pfizer fo...ll continue to have operations at Chesterfield Vil...
(Date:11/9/2009)...VIRGINIA BEACH, Va., Nov. 9 LifeNe... announces the launch of Vertigraft Cervical Bio-I..., Preservon® is a new, proprietary glycerol-b...io-implants to be stored in a fully hydrated state...to freeze or freeze-dry bio-implants, doing away w...
Breaking Medicine Technology:Royal Institute of Technology Adopts OriGene Over-Expression Lysates in Human Proteome Atlas Program 2Monsanto to Purchase Chesterfield Village Research Center From Pfizer 2Monsanto to Purchase Chesterfield Village Research Center From Pfizer 3LifeNet Health Announces First Bio-Implant with New Preservation Technology 2Gene Therapy Shows Promise for Parkinsons 59471 1Gene Therapy Shows Promise for Parkinsons 59471 2Gene Therapy Shows Promise for Parkinsons 59471 3Experts Summarize State of the Science in Autism Disorders 59468 1Experts Summarize State of the Science in Autism Disorders 59468 2Experts Summarize State of the Science in Autism Disorders 59468 3Experts Summarize State of the Science in Autism Disorders 59468 4Jack LaLanne Celebrated as Fitness Icon at Star Studded Birthday Bash 59465 1Jack LaLanne Celebrated as Fitness Icon at Star Studded Birthday Bash 59465 2
...antly Reduced Signs of Disease Activity as Measure..., 2007 -- Genentech, Inc.,(NYSE: DNA) and Biogen... data from a Phase II clinical study of Rituxan&re...g multiple sclerosis,(RRMS) were presented today a... held in Boston. Rituxan is a therapeutic antibody...
...tzerland, May 2, 2007 – Merck,Serono S.A. (v...,safinamide, a new agent in Phase III development ...ptoms, were presented by Professor,Fabrizio Stocch...,Meeting in Boston, Massachusetts, USA. These data... blind, placebo-controlled,international trial. ,...
Other Medicine Technology:Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 2Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 3Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 4Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 5
VitalWorks Intuition PM Ophthalmology
...ITER Electronic Medical Records (including ExamDRA... record instrument in the industry. Doctors and st...effortless speed and accuracy using our trademarke...ed for typing, we have created the fastest, easies...
Simplex™ P Bone Cement
...1 Gentamicin Bone Cement, a high viscosity antibio...ional market for over a decade, eliminates the inc...e premixed powder helps to prevent inconsistency i...cin Bone Cement provides the same proven character...
Medicine Products: